SMS Pharmaceuticals Limited
NSE: SMSPHARMA BSE: SMSPHARMA
Prev Close
358
Open Price
360
Volume
1,292,779
Today Low / High
354.7 / 387.5
52 WK Low / High
176.05 / 387.5
Range
354 - 391
Prev Close
357.95
Open Price
358.65
Volume
30,431
Today Low / High
355.9 / 387
52 WK Low / High
175 / 387
Range
354 - 392
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 372.45 (target range: 354 - 391), reflecting a change of 14.45 (4.03631%). On the BSE, it is listed at 372.9 (target range: 354 - 392), showing a change of 14.95 (4.17656%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
SMS Pharmaceuticals Limited Graph
SMS Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for SMS Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 372.45, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 372.90 | 376.63 | 338.97 - 414.29 |
| 380.36 | 304.29 - 456.43 | ||
| 384.09 | 268.86 - 499.31 | ||
| Bearish Scenario | 372.90 | 369.17 | 332.25 - 406.09 |
| 365.44 | 292.35 - 438.53 | ||
| 361.71 | 253.20 - 470.23 |
Overview of SMS Pharmaceuticals Limited
ISIN
INE812G01025
Industry
Drug Manufacturers - General
Vol.Avg
618,317
Market Cap
34,880,687,400
Last Dividend
0.4
Official Website
IPO Date
2007-02-28
DCF Diff
724.26
DCF
-352
Financial Ratios Every Investor Needs
Stock Dividend of SMSPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-22 | September 22, 25 | 0.4 | 0.4 | 2025-09-22 | 2025-10-29 | |
| 2024-09-23 | September 23, 24 | 0.4 | 0.4 | 2024-09-23 | 2024-10-30 | |
| 2023-09-22 | September 22, 23 | 0.3 | 0.3 | 2023-09-22 | 2023-10-29 | |
| 2022-09-22 | September 22, 22 | 0.3 | 0.3 | 2022-09-23 | 2022-10-30 | |
| 2021-09-22 | September 22, 21 | 0.3 | 0.3 | 2021-09-23 | 2021-10-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 782.75 Cr | 637.83 Cr | 144.92 Cr | 0.1851 | 12.83 Cr | 7.42 Cr | 103.32 Cr | 69.14 Cr | 8.15 | 145.22 Cr | 0.0883 |
| 2024-03-31 | 709.26 Cr | 498.33 Cr | 210.94 Cr | 0.2974 | 11.11 Cr | 64.22 Cr | 134.01 Cr | 49.83 Cr | 5.89 | 117.53 Cr | 0.0703 |
| 2023-03-31 | 522.05 Cr | 393.13 Cr | 128.92 Cr | 0.2469 | 8.92 Cr | 5.59 Cr | 21.34 Cr | -7.06 Cr | -0.83 | 59.39 Cr | -0.0135 |
| 2022-03-31 | 515.02 Cr | 333.59 Cr | 181.43 Cr | 0.3523 | 8.39 Cr | 4.95 Cr | 78.98 Cr | 62.22 Cr | 7.35 | 119.53 Cr | 0.1208 |
| 2021-03-31 | 560.82 Cr | 379.39 Cr | 181.43 Cr | 0.3235 | 7.35 Cr | 4.11 Cr | 97.67 Cr | 62.53 Cr | 7.39 | 124.56 Cr | 0.1115 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 41.59 Cr | 1,152.68 Cr | 513.04 Cr | 639.6443 Cr | 310.76 Cr | 269.17 Cr | 284.73 Cr | 565.52 Cr | 0.00 Cr | 0.00 Cr | 11.68 Cr | 324.3686 Cr |
| 2024-03-31 | 36.04 Cr | 1,034.09 Cr | 497.76 Cr | 536.3289 Cr | 280.77 Cr | 244.73 Cr | 233.70 Cr | 478.74 Cr | 0.00 Cr | 0.00 Cr | 10.94 Cr | 331.7184 Cr |
| 2023-03-31 | 7.38 Cr | 879.61 Cr | 419.08 Cr | 460.5252 Cr | 254.07 Cr | 246.69 Cr | 223.50 Cr | 443.74 Cr | 6.55 Cr | 0.00 Cr | 11.45 Cr | 254.9135 Cr |
| 2022-03-31 | 46.58 Cr | 859.50 Cr | 389.21 Cr | 470.2886 Cr | 263.27 Cr | 216.69 Cr | 251.10 Cr | 447.63 Cr | 1.25 Cr | 0.00 Cr | 21.53 Cr | 196.4803 Cr |
| 2021-03-31 | 40.42 Cr | 812.21 Cr | 401.68 Cr | 410.5280 Cr | 254.58 Cr | 214.16 Cr | 137.79 Cr | 462.50 Cr | 22.62 Cr | 0.00 Cr | 26.85 Cr | 195.4294 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 64.5230 Cr | -123.5956 Cr | 64.4322 Cr | -58.8568 Cr | 5.3596 Cr | 41.5861 Cr | -123.3798 Cr | 69.1356 Cr | 30.4302 Cr | -3.3861 Cr | -51.0313 Cr |
| 2024-03-31 | 50.1247 Cr | -52.0720 Cr | 30.6790 Cr | -2.0353 Cr | 28.7317 Cr | 36.0395 Cr | -52.1600 Cr | 49.8260 Cr | 27.5298 Cr | -2.5396 Cr | -10.1984 Cr |
| 2023-03-31 | 22.4500 Cr | -29.6861 Cr | -31.9689 Cr | -7.4707 Cr | -39.2050 Cr | 7.3778 Cr | -29.9207 Cr | 5.3491 Cr | -7.7671 Cr | -2.5396 Cr | 27.5981 Cr |
| 2022-03-31 | 40.2337 Cr | -27.1530 Cr | -6.9210 Cr | 12.9863 Cr | 6.1597 Cr | 46.5828 Cr | -27.2474 Cr | 68.4991 Cr | 9.4075 Cr | -2.5395 Cr | -113.3102 Cr |
| 2021-03-31 | 90.4534 Cr | -151.5923 Cr | 92.0178 Cr | -61.2956 Cr | 30.8789 Cr | 40.4231 Cr | -151.7490 Cr | 91.1198 Cr | 98.1617 Cr | 0.0000 Cr | -8.5871 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 210.45 Cr | 166.63 Cr | 43.82 Cr | 0.2082 | 33.63 Cr | 23.47 Cr | 2.59 | 47.40 Cr | 0.1115 |
| 2025-09-30 | 242.43 Cr | 165.56 Cr | 76.87 Cr | 0.3171 | 38.34 Cr | 25.31 Cr | 2.84 | 49.80 Cr | 0.1044 |
| 2025-06-30 | 196.05 Cr | 130.70 Cr | 65.35 Cr | 0.3333 | 29.62 Cr | 20.49 Cr | 2.31 | 39.96 Cr | 0.1045 |
| 2025-03-31 | 248.20 Cr | 208.59 Cr | 39.61 Cr | 0.1596 | 32.17 Cr | 20.32 Cr | 2.39 | 42.23 Cr | 0.0819 |
| 2024-12-31 | 173.35 Cr | 106.24 Cr | 67.11 Cr | 0.3871 | 24.51 Cr | 18.24 Cr | 2.15 | 35.34 Cr | 0.1052 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 99.49 Cr | 2.57 Cr | 102.06 Cr | 221.42 Cr | 317.47 Cr | 661.15 Cr | 567.52 Cr | 1,276.46 Cr | 547.11 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 41.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -639.64 Cr |
| 2025-03-31 | 41.59 Cr | 0.00 Cr | 41.59 Cr | 203.23 Cr | 284.73 Cr | 554.47 Cr | 565.52 Cr | 1,152.68 Cr | 513.04 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 9.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -563.55 Cr |
| 2024-09-30 | 8.90 Cr | 11.99 Cr | 20.89 Cr | 213.38 Cr | 315.27 Cr | 581.94 Cr | 518.41 Cr | 1,134.73 Cr | 571.18 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 20.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 20.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 18.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 14.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 16.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-12-17 | December 17, 15 | 10:1 |
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,341.10 | ₹1,083,314,665,925.00 | ₹1,551,704.00 |
| Abbott India Limited | ABBOTINDIA | ₹26,295.00 | ₹558,750,396,090.00 | ₹7,694.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,596.90 | ₹439,930,529,695.00 | ₹39,078.00 |
| Gland Pharma Limited | GLAND | ₹1,821.70 | ₹300,136,775,779.00 | ₹16,533.00 |
| Pfizer Limited | PFIZER | ₹4,931.70 | ₹225,614,089,904.00 | ₹10,105.00 |
| Sanofi Consumer Healthcare India Ltd. | SANOFICONR | ₹4,044.60 | ₹93,149,653,741.00 | ₹2,673.00 |
| Sanofi India Limited | SANOFI | ₹4,026.10 | ₹92,723,587,234.00 | ₹7,749.00 |
| Marksans Pharma Limited | MARKSANS | ₹178.38 | ₹80,835,349,011.00 | ₹438,114.00 |
| Senores Pharmaceuticals Ltd. | SENORES | ₹810.30 | ₹37,317,222,356.00 | ₹76,440.00 |
| SMS Pharmaceuticals Limited | SMSPHARMA | ₹372.45 | ₹34,880,687,400.00 | ₹1,292,779.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1962
Gender: male
Year Born: 1958
Gender: male
Year Born:
Gender: male
Year Born: 1988
Gender: male
Year Born: 1964
FAQs about SMS Pharmaceuticals Limited
The CEO is Ramesh Babu Potluri.
The current price is ₹372.45.
The range is ₹176.05-387.5.
The market capitalization is ₹3,488.07 crores.
The dividend yield is 0.11%.
The P/E ratio is 37.68.
The company operates in the Healthcare sector.
Overview of SMS Pharmaceuticals Limited (ISIN: INE812G01025) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹3,488.07 crores and an average daily volume of 618,317 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹0.4.